BIOLINERX LTD-SPONS ADR (BLRX)
US09071M2052 - ADR
BioLineRx Announces $6 Million Registered Direct Offering
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick.
BioLineRx files for a $250M mixed securities shelf (NASDAQ:BLRX)
BioLineRx (BLRX) has filed a prospectus for a mixed shelf offering to raise up to $250M, indicating potential growth in their financial capital.
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
biolinerx GAAP EPS of -$0.01 (NASDAQ:BLRX)
BiolineRx, a biopharmaceutical company, reports Q3 2023 financial results, with a GAAP EPS of -$0.01.
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent...
3 Tech Stocks That Wall Street Loves More Than Nvidia
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market.
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Penny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall.
BioLineRx announces closing of exclusive license agreement with GloriaBio (NASDAQ:BLRX)
BioLineRx announced a license agreement with GloriaBio for the development of motixafortide in Asia, including potential milestones and equity investment.
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
- License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential...
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx stock gains after first FDA approval (NASDAQ:BLRX)
BioLineRx (BLRX) added ~23% pre-market Monday after the FDA greenlighted its lead asset Aphexda (motixafortide) for multiple myeloma patients. Read more here.
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple...
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors.
3 Smart Penny Stocks with Huge Potential
Find a similar success story in some of the market's top penny stocks, and you stand to make a small fortune.
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain...
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead.
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will...
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
NASDAQ:BLRX Long Term Shareholder Alert: Investigation of Potential Wrongdoing at BioLineRx Ltd.
San Diego, CA -- (SBWIRE) -- 04/24/2023 -- An investigation was announced for current long-term investors in shares of BioLineRx Ltd. (NASDAQ:BLRX) concerning potential breaches of fiduciary duties by certain directors of BioLineRx Ltd.
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints - - Nature Medicine publication describes how GENESIS...
The 3 Best Biotech Stocks Under $1 to Buy for April
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider.